More than 1 in 8 positions are vacant in the agency’s Center for Drug Evaluation and Research, which is responsible for drug testing and approvals, according to a report jointly published by Kaiser Health News and The Washington Post. That means 711 jobs are currently unfilled, though many are newly created positions, according to the report.
Sources told KHN part of the problem is the FDA can’t offer salaries as competitive as those offered by pharmaceutical companies. And, when a person gets an FDA job, they have to divest stocks in companies that present conflicts of interest.
The 21st Century Cures Act, which awaits Senate approval, could help the issue, according to the report. It includes adjustments to existing laws that makes the prerequisites for FDA jobs more lenient and gives the FDA authority to set pay up to $400,000, according to the report.
Read the full report here.
More articles on supply chain:
Valeant considers selling $2.5B eye-surgery equipment branch
Building up, not out: Prologis to open first 3-story US distribution center
Northern Mexico border sees industrial lease slump amid concerns of Trump presidency
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.